LLYEli Lilly and CompanyRunning, no new patients
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 152 (planned)
- Started
- Dec 20, 2021
- Main results expected
- Jan 12, 2026
- Fully finished
- May 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-Free Survival (EFS)
Measured over: Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04819100 · record last updated 2026-03-04 · checked 2026-11-09 15:36 UTC